Mastering Immunity Europe 2019

Dr. Jonathan Silk

Adaptimmune

“Next Generation approaches to enhance the efficacy of SPEAR T-cells”

Dr. Marie Toussaint

GSK

“How to develop the vaccines of tomorrow”

Dr. Christos Georgiadis

Institute of Child Health, UCL

“Coupled Long Terminal-CRISPR Gene Editing for the Redirection of T cells”

Dr. Jeremy Fry

ProImmune

“An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design”

Clemens Joos

Helmholtz Centre, Munich

“Gene transfer of MHC II-restricted CMV-specific TCRs for development of immunotherapy”

Dr. Tom Evans

Vaccitech

“Heterologous prime-boost approaches to CD8+ T cell induction”

Mastering Immunity 2018

Dr. Marcus Butler

UHN Toronto

“Optimizing Adoptive T cell Therapies”

Dr. Marianne Stanford

VP Research, IMV

“De novo generation of tumor specific T cell responses utilizing a novel oncology driven delivery platform”

Dr. Emilee Knowlton

ProImmune

“Epitope identification and clinical immune monitoring in gene therapy and immune oncology program”

Dr. Priya Sriraman

Celgene

“Measuring Host-vs-CAR-T Immune Responses”

Dr. Zuben Sauna

FDA

“Use of the MHC Associated Peptide Proteomic (MAPPs) assay to understand clinical outcomes associated with the use of Factor VIII in the treatment of Hemophilia A”

Dr. Shahla Abdollahi

Celgene

“Mechanisms of Immune Modulation by the Gut Microbiome – Implications for Autoimmunity”

Dr. Amy Rosenberg

FDA

“So You Think You Have Mastered Immunity? Cautionary Tales from the Immunology Revolution”

Dr. Jeremy Fry

ProImmune

“An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design”

Dr. Jochem Gokemeijer

Bristol-Myers Squibb

“Immunogenicity Risk Assessment Tool Box for Biologics Drug Development”

Dr. Sophie Tourdot

Pfizer

“Non-clinical immunogenicity risk assessment of therapeutic proteins”

Dr. Andrea Ferrante

Lilly

“In silico prediction of immunogenicity: filling the gaps”

Dr. Rodd Polsky

GSK

“Format and Interpretation of a Drug Tolerant Approach for Measuring Circulating Immune Complex and Free Anti-Drug Antibodies in Preclinical Studies”

Dr. Jad Maamary

Merck & Co.

“In Silico and In Vitro Tools to Investigate Increased Immunogenicity Incidence Observed in Combination Therapies”

Mastering Immunity Europe 2018

Dr. Lotta Jansson

Apitope

“Apitopes to induce immune tolerance - mechanism and action”

Dr. Aileen Rowan

Imperial College, London

“Turnover and transformation of T cell clones in retroviral infection and leukaemia”

Prof. Paul Brenchley

University of Manchester

“Identifying T & B Cell autoantigen epitopes in Autoimmune Membranous Nephropathy”

Dr. Margot El-Khouri

ProImmune

“Epitope identification and clinical immune monitoring in immune oncology programs”

Dr. Yongliang Zhang

National University Singapore

“DUSP10 in inflammation and cancer”

Dr. Guy Hermans

Isogenica

“Using synthetic antibody libraries to overcome poor immunogenicity”

Dr. Katie Ewer

University of Oxford

“Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children”

Dr. Ilaria Esposito

University of Oxford

“Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV”

Dr. Isabelle Turbica

Université Paris-Sud

“Impact of protein aggregates from biopharmaceuticals on dendritic cells”

Dr. Eleni Chantzoura

Agenus

“Mammalian Display for TCR discovery & Phosphopeptide neoantigens as targets”

Dr. Joleen White

EMD Serono

“Low Immunogenicity of Avelumab, An Immune Checkpoint Inhibitor Demonstrating Antitumor Activity”

Dr. Richard Sainson

Kymab

“Long-term in vivo anti-tumour efficacy of KY1044 (anti-ICOS) as monotherapy and in combination with anti-PD-L1”

Dr. Stephen Man

Cardiff University School of Medicine

“CD8+ T cell recognition of unusual and unnatural peptide epitopes”

Prof. Beatriz Carreno

University of Pennsylvania

“Personalized Cancer Vaccines”

Prof. Fiona Powrie

University of Oxford

“Host microbe interactions in the intestine: New therapeutic strategies in IBD”

Mastering Immunity 6 (2017)

Dr. Valerie Quarmby

Genentech

“Host Cell Proteins and Immunogenicity”

Dr. Daron Forman

Bristol-Myers Squibb

“The use of immunogenicity risk assessment tools for lead optimization of biologics”

Dr. Erik Meyer

GlaxoSmithKline

“Therapeutic Immunogenicity: Target Interference and Cut Point Evaluation”

Dr. Wojciech Jankowski

FDA

“Non-clinical Assessments of Immunogenicity”

Dr. Eric Zanelli

Déclion Holdings

“DP-C016, a phosphoTau vaccine for the treatment of tauopathies”

Dr. Nik Schwabe

ProImmune

“Epitope identification and clinical immune monitoring in immune oncology programmes”

Mr Govinda Sharma

British Columbia Cancer Agency

“Functional identification of CD8+ T cell epitopes by parallel interrogation of more than a million distinct peptide-coding sequences”

Dr. Scott McClain

Syngenta Crop Protection

“Bioinformatic screen and detection of immunologically relevant cross-reactive IgE-binding epitopes”

Mastering Immunity Europe 2017

Dr. Bernard Maillère

CEA, France

“Specificity and phenotype of pre-existing T cells against therapeutic proteins”

Dr. Menna Clatworthy

University of Cambridge, UK

“Immune complexes modulate immune highways and DC trafficking”

Prof. Farzin Farzaneh

King's College London, UK

“Therapeutic Cancer Vaccines”

Dr. Bartek Zuber

Swedish Orphan Biovitrum, Sweden

“Immunogenicity assessment for Affibody-Fc fusion therapeutics”

Dr. Tim Hickling

Pfizer, USA

“Applying in vitro immunogenicity assays to predicts clinical immunogenicity”

Dr. Sophie Sibéril

UPMC, Paris, France

“Analysis of peripheral T cell compartments in high-grade Follicular Lymphoma patients treated with rituximab-based regimens”

Prof. Yu-Chan Chao

Academia Sinica, Taiwan

“Display of foreign surface antigens on baculovirus as pseudotyped viruses for immunological studies and applications”

Prof. Tim Elliott

University of Southampton, UK

“Applying mechanism based computational models to CTL epitope prediction”

Prof. Mark Exley

Agenus Inc., USA

“Phosphopeptide NeoAntigens for Tumor Immunity: Novel therapeutic options”

Prof. Christine Falk

Medizinische Hochschule Hannover, Germany

“Precision Medicine in Transplantation - immune monitoring for the discrimination of GVHD, rejection and CMV infection”

Prof. Miles Carroll

Public Health England, UK

“Understanding the immune response to EBOV during acute disease and in EVD survivors”

Mastering Immunity Europe 2016

Prof. Herman Waldmann

University of Oxford

“Short-term therapeutic intervention for the therapeutic harnessing of tolerance mechanisms”

Dr. Farnaz Fallah-Arani

UCB Pharma, UK

“Challenges to experimental design to test immunotherapeutic drugs to achieve clinically relevant results.”

Dr. Bernd Schlereth

Covagen, Switzerland

“Special considerations in pharmacokinetic and immunogenicity assessment of bispecific antibody constructs”

Dr. Bernard Maillère

CEA, France

“Comprehensive analysis of pre-existing T cells specific to therapeutic proteins in healthy donors”

Prof. David Wraith

University of Bristol

“Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”

Dr. Peter Adler Wurtzen

ALK-Abelló, Denmark

“Immunological biomarkers in Allergy Immunotherapy”

Prof. Paul Moss

University of Birmingham

“Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”

Prof. Ada Kruisbeek

DCPrime, The Netherlands

“Developing off-the-shelf dendritic cell based vaccines: pre-clinical and clinical observations”

Dr. Wei Xue

Roche Innovation Center Zurich, Switzerland

“Combination immunotherapy and vaccines in cancer”

Mastering Immunity 5 (2015)

Dr. Ethan Shevach

NIAID, NIH

“Tregs -ready for the clinic”

Dr. Keith Knutson

Mayo Clinic, Jacksonville

“Vaccines for Prevention of Breast Cancer”

Prof. Jean Rommelaere

DKFZ, Germany

“Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”

Dr. Xiaoying Chen

Pfizer, Inc.

“A Systems Pharmacology Approach to Immunogenicity – A multi-scale, Mechanistic Mathematical Model and Its Applications”

Prof. Armagan Kocer

University of Groningen

“Ion channel decorated liposomes: therapeutic potential and immunogenicity”

Prof. David Wraith

University of Bristol

“Switching off immunity: the mechanism of antigen-specific immunotherapy”

Prof. Julio Delgado

University of Utah

“Assessment of TNF-alpha antagonists and Anti-Drug Antibodies in the Clinical Laboratory”

Dr. Gene Olinger

NIAID, NIH

“Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans”

Prof. Lawrence Steinman

Stanford University

“Vaccines, adjuvants, and autoimmunity”

Mastering Immunogenicity 4 (2014)

Prof. Herman Waldmann

University of Oxford

“Tolerance can be induced in the adult immune system”

Prof. Arlene Sharpe

Harvard University

“T Cell Coinhibitory Pathways and Cancer Immunotherapy: Roles of the PD-1 pathway in controlling tolerance and tumor immunity”

Dr. Timothy Hickling

Pfizer, Inc.

“Contribution of ex vivo assays to immunogenicity risk assessment”

Dr. Sabine Zollner

CSL Behring

“Preclinical characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII under clinical development at CSL Behring”

Dr. Nades Palaniya

The Hospital for Sick Children, Toronto

“Targeting innate immune collectins and neutrophil extracellular traps (NETs) to regulate inflammatory diseases”

Dr. Joleen White

Biogen IDEC

“Evaluation of Peginterferon Beta-1a and Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Immunogenicity in Multiple Sclerosis”

Dr. Bruce Hall

University of New South Wales

“Antigen specific CD4+CD25+Foxp3+Treg generated from natural Treg (nTreg)”

Dr. Amy Loercher

GSK

“ABIRISK Developments and Challenges: Perspectives from Year 2”

Dr. Susan Kirshner

FDA

“Therapeutic Proteins: Routes of Exposure and the risk of immunogenicity”

Mastering Immunogenicity 3 (2013)

Prof. David Wraith

University of Bristol

“Dealing with Unwanted Immunogenicity: The Design and Development of Tolerogenic T Cell Epitopes”

Dr. Florian Deisenhammer

Innsbruck

“Drug Immunogenicity: Lessons Learnt from Interferon-beta”

Dr. Beth Chang

Amunix

“XTEN in Blood Factor Engineering”

Dr. William Sanderson

University College London

“Phenotypic Structure of B Cell Subsets as a Tool for the Investigation for Immunogenicity”

Dr. Michael Cancro

University of Pennsylvania

“B Cell Selection and Survival: First Order Consideration for Immunogenicity”

Dr. Larry Kauver

Trellis

“Antibody Repertoire Monitoring: Application to Anti-Drug Antibodies”

Dr. Samuel Pine

Allergan

“Immunologic Endpoints for Guiding Biologic Drug Development”

Dr. Caroline Barelle

University of Aberdeen

“Shark VNAR Domains: Immunogenicity Determination in the Early Stages of Development Aids Candidate Selection for "First-Man" Studies”

Dr. Federico Mingozzi

University Pierre et Marie Curie

“Assessing and Modulating Immune Responses to AVV Vectors in Humans”

Mastering Immunogenicity 2 (2012)

Dr. Manoj Rajadhyaksha

Regeneron

“Working towards building a “Value Added Proposition” for Immunogenicity Prediction and Risk Management”

Dr. Bonnie Rup

Pfizer

“Understanding the problem of unwanted immunogenicity risk in biotherapeutic discovery and development: advances, gaps, opportunities”

Dr. Nikolai Schwabe

ProImmune

“Mastering Immunity: ProStorm™ Cytokine Release Assay”

Dr. Bob DuBridge

Full Spectrum Genetics

“MapEng™ A Powerful, New Tool in the Engineering of Biobetter Therapeutics”

Best Practice Immunogenicity Risk Management (2012)

Dr. Tim Hickling

Pfizer

“Immunogenicity of biotherapeutics: Why do we care and where do we stand?”

Dr. Robin Thorpe

NIBSC Health Protection Agency

“CHMP Guidance on Unwanted Immunogencity: Best Practice Iummunogenicity Risk Management: Oxford 2012”

Dr. Katharina Steinitz

Baxter Innovations GmbH

“Identification of promiscuous FVIII-specific CD4+ T-cell epitopes in a humanized mouse model for hemophilia A”

Dr. Heather Hinton

Roche

“Pre-Clinical Risk Assesment Using Innovative Technologies”

Dr. David Ulaeto

DSTL

“Therapeutic potential of a humanised antibody for the treatment of Venezuelan Equine Encephalitis Virus”